References

  1. Leiwen F, Bingyi W, Tanwei Y, et al. “Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis.” J Infect. 2020; 80(6): 656–665.
  2. Lei W, Yin S, Man L, Haoyu C, et al. “Clinical manifestations and evidence of neurological involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis.” J Neurol. 2020; 11: 1–13.
  3. Sarah Y and Anthony P. Fernandez. “Skin Manifestations of COVID-19.” Cleveland Clinic Journal of Medicine, 2020; 87(6): 1-4.
  4. Hamming I, Timens W, Bulthuis MLC, et al. “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.” Journal of Pathology, 2004; 203(2): 631–637.
  5. Li Y-C, Bai W-Z, Hashikawa T. “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients” Med Virol, 2020; 92:552–555.
  6. Mao L, Jin H, Wang M, et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China.” JAMA Neurol, 2020; 77(6): 683-690.
  7. Mark AE, Laura B, Bhagteshwar S, et al. “Neurological associations of COVID-19.” Lancet Neurol, 2020; 19 (9) 1-17.
  8. Gaurav N, Jessica HR, Gentle SS, et al. “Neurological manifestations of COVID-19: a systematic review.” Critical Care, 2020; 24(421): 1-11.
  9. Christian R, Marc M, Jörg B, et al. “Hemifacial Spasm: Conservative and Surgical Treatment Options.” Dtsch Arztebl Int. 2012; 109(41): 667–673.
  10. Hutchins KL, Jansen JH, Comer AD, et al. “COVID-19–Associated Bifacial Weakness with Paresthesia: A Subtype of Guillain-Barré Syndrome.” Am J Neuroradiology, 2020; 1-5.
  11. Stefan CAH and Angela W. “Diagnosis and Treatment of Vestibular Neuritis/Neuronitis or Peripheral Vestibulopathy (PVP)? Open Questions and Possible Answers.” Otology & Neurotology, 2017; 38(5): 1-6.
  12. Srikrishna VM, Ambreen R. “A Case of COVID-19-Induced Vestibular Neuritis.” Cureus, 2020; 12(6).
  13. Robert WB. “Vestibular Neuritis.” N Engl J Med, 2003; 348:1027-32.
  14. Michael S, Vera CZ, Viktor A, et al. “Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis.” N Engl J Med, 2004; 351:354-61.
  15. Mark FW. “Treatment of Vestibular Neuritis.” Current Treatment Options in Neurology, 2009; 11:41–45.
  16. Michael G and Brit L. “Dermatologic manifestations and complications of COVID-19.” Am J Emerg Med, 2020; 38(9): 1715–1721.
  17. Muskaan S, Raffaele G, Monica S, et al. “Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.” J Dermatol Sci, 2020. 98(2): 75-81.
  18. Athanassios K, Florence D, Daphné D, et al. “Coronavirus (COVID-19) infection–induced chilblains: A case report with histopathologic findings.” JAAD Case Rep, 2020; 6(6): 489–492.
  19. Sergio VG and Antonio M. “Chilblains.” CMAJ, 2012; 184(1): 67.
  20. Katherine KT. “A Review of Raynaud’s Disease.” Mo Med, 2016; 113(2): 123–126.
Author contribution: All the authors contributed equally to the manuscript including review of literaure, intervewing the patient and writing the manuscript.
Figure legend: Raynaud’s phenomenon during the acute COVID-19 infection with bluish discoloration of the extremities
Conflict of interest: Authors do not report any conflict of interest.
Ethical approval: Not Applicable
Funding information: Not applicable.
Acknowledgements: None